Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 2Plasma cell 1Other hematologic neoplasm 1

Conditions

Multiple Myeloma 1Common Variable Immunodeficiency 1Agammaglobulinemia 1

Interventions

Dexamethasone 479Lenalidomide 297Cyclophosphamide 271Bortezomib 267Melphalan 212Calcium Dobesilate 189fludarabine phosphate 121daratumumab 121Peripheral Blood Stem Cell Transplantation 101fludarabine 99carfilzomib 98Thalidomide 94pomalidomide 92Filgrastim 92Whole-Body Irradiation 88Mycophenolic Acid 88Busulfan 80Tacrolimus 75Granulocyte Colony-Stimulating Factor 72dexamethasone acetate 65ixazomib 62Cyclosporine 59dexamethasone 21-phosphate 56Antilymphocyte Serum 51auricularum 50isatuximab 44Radiotherapy 41Etoposide 40Stem Cell Transplantation 39Methotrexate 33

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Hizentra × Plasma cell × Clear all
NCT06976476 2026-03-11

Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
100 enrolled
Plasma cell

Agammaglobulinemia, Multiple Myeloma, Common Variable Immunodeficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡